E2F1 has been proposed as a candidate for the regulation of LSCs quiescence in CML due to its role in controlling the G1-S phase transition and because of its increased expression at the level of CD34+ cells [64,65]. This evidence concerns the gene E2F1 and chronic myelogenous leukemia, BCR-ABL1 positive.